Literature DB >> 32978504

Overexpressed sFRP3 exerts an inhibitory effect on hepatocellular carcinoma via inactivation of the Wnt/β-catenin signaling pathway.

Long Fang1, Chun Gao1, Ru-Xue Bai1, Hui-Fen Wang1, Shi-Yu Du2.   

Abstract

Hepatocellular carcinoma (HCC) is recognized as the most common malignancy of the liver in adults. Many human cancers have been associated with the oncogenic activation of the Wnt/β-catenin signaling pathway. The secreted frizzled-related proteins (sFRPs) function as negative regulators of the Wnt signaling and have important implications in carcinogenesis. This study aims to investigate the possible regulatory effects of sFRP3 on the Wnt/β-catenin signaling pathway and their interactions in HCC occurrence. Firstly, sFRP3 expression was quantified in the collected cancer and adjacent normal tissue samples from HCC patients. The lowly expressed sFRP3 in HCC tissues was found to be correlated with HCC development. The expression of sFRP3 was regulated by a lentivirus-based packaging system, and the Wnt/β-catenin signaling pathway was inactivated by DDK-1 in HepG2 cells. The expressions of Wnt1, β-catenin and the nuclear translocation of β-catenin were determined, both of which were down-regulated by sFRP3 overexpression. CCK8 assay, EdU staining, Colony formation assay, flow cytometry, scratch test and Transwell assay were employed to test cell viability, proliferation, cell cycle, apoptosis, migration and invasion, respectively. Overexpressed levels of sFRP3 were found to produce a reduction in MMP-2, MMP-7, MMP-9, PCNA, Ki67, and Bcl-2 expressions but an increase in the expressions of caspase-3 and Bax. In addition, overexpression of sFRP3 inhibited cell proliferation, migration, invasion, and colony formation, but promoted cell cycle arrest and cell apoptosis in HCC cells. The addition of the Wnt/β-catenin signaling pathway inhibitor, DKK-1, reversed the contributory effect of sFRP3 silencing on HCC development. Lastly, in vivo tumor formation was inhibited by enforced sFRP3 expressions. The obtained results suggested that sFRP3 acts as an anti-oncogene in HCC by inhibiting the activation of the Wnt/β-catenin signaling pathway.
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32978504     DOI: 10.1038/s41417-020-0201-z

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  39 in total

1.  Risk factors for major morbidity after liver resection for hepatocellular carcinoma.

Authors:  H Sadamori; T Yagi; S Shinoura; Y Umeda; R Yoshida; D Satoh; D Nobuoka; M Utsumi; T Fujiwara
Journal:  Br J Surg       Date:  2012-11-22       Impact factor: 6.939

2.  Dynamic expression of secreted Frizzled-related protein 3 (sFRP3) in the developing mouse spinal cord and dorsal root ganglia.

Authors:  X Zhao; H Huang; Y Chen; Y Liu; Z Zhang; Q Ma; M Qiu
Journal:  Neuroscience       Date:  2013-07-01       Impact factor: 3.590

Review 3.  Risk factors of hepatocellular carcinoma--current status and perspectives.

Authors:  Jing Gao; Li Xie; Wan-Shui Yang; Wei Zhang; Shan Gao; Jing Wang; Yong-Bing Xiang
Journal:  Asian Pac J Cancer Prev       Date:  2012

4.  Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.

Authors:  Xiaolin Zi; Yi Guo; Anne R Simoneau; Christopher Hope; Jun Xie; Randall F Holcombe; Bang H Hoang
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

Review 5.  Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.

Authors:  Jens U Marquardt; Peter R Galle; Andreas Teufel
Journal:  J Hepatol       Date:  2011-07-23       Impact factor: 25.083

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation.

Authors:  Ying Qu; Jian-Fang Li; Qu Cai; Yun-Wei Wang; Qin-Long Gu; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-07       Impact factor: 4.553

Review 8.  New possibilities in hepatocellular carcinoma treatment.

Authors:  Mahmood Rasool; Sana Rashid; Mahwish Arooj; Shakeel Ahmed Ansari; Khalid Mahmud Khan; Arif Malik; Muhammad Imran Naseer; Sara Zahid; Abdul Manan; Muhammad Asif; Zarish Razzaq; Sadia Ashraf; Mahmood Husain Qazi; Zafar Iqbal; Siew Hua Gan; Mohammad Amjad Kamal; Ishfaq Ahmed Sheikh
Journal:  Anticancer Res       Date:  2014-04       Impact factor: 2.480

Review 9.  Hepatitis B precore protein: pathogenic potential and therapeutic promise.

Authors:  Renae Walsh; Stephen Locarnini
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

Review 10.  Tumor markers for hepatocellular carcinoma.

Authors:  Yan-Jie Zhao; Qiang Ju; Guan-Cheng Li
Journal:  Mol Clin Oncol       Date:  2013-05-13
View more
  1 in total

1.  CTB-193M12.5 Promotes Hepatocellular Carcinoma Progression via Enhancing NSD1-Mediated WNT10B/Wnt/β-Catenin Signaling Activation.

Authors:  Shuhua Zhang; Mi Jiang; Huan Cao; Jun Xiong; Jianqun Xu
Journal:  J Hepatocell Carcinoma       Date:  2022-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.